Intec Pharma to Participate at Upcoming June Conferences
Intec Pharma Ltd. (Nasdaq:NTEC)(TASE:NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its
proprietary Accordion Pill™ platform technology, announces that the company will participate at the following two upcoming June
conferences:
|
LD Micro Invitational
|
| Date and Time: |
|
Tuesday, June 6, 2017, 8:00 a.m. Pacific Time |
| Venue: |
|
Luxe Sunset Boulevard Hotel, Los Angeles, CA |
| Format: |
|
Company presentation |
| Presenter: |
|
John Kozarich, Ph.D., Chairman of the Board |
| |
|
Jefferies 2017 Global Healthcare Conference
|
| Date and Time: |
|
Friday, June 9, 2017, 9:00 a.m. Eastern Time |
| Venue: |
|
Grand Hyatt, New York, NY |
| Format: |
|
Company presentation |
| Presenter: |
|
Jeffrey Meckler, Vice Chairman |
| |
Dr. Kozarich’s and Mr. Meckler’s presentations will be webcast live and can be accessed on the Investor Relations section of the
Company’s website at www.intecpharma.com where they will be archived for a period of time.
About Intec Pharma Ltd.
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion
Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and
safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The
Company's product pipeline includes four product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or
AP-CD/LD, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients;
Accordion Pill Zaleplon, or AP-ZP, which is being developed for the treatment of insomnia, including sleep induction and the
improvement of sleep maintenance; an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and
small bowel Nonsteroidal Anti-Inflammatory Drug (NSAID)-induced ulcers; and AP-CBD/THC, an Accordion Pill with the two primary
cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed for
various indications including low back neuropathic pain and fibromyalgia.
Intec Pharma
John Kozarich, Ph.D.
Chairman of the Board
john@intecpharma.com
or
LHA Investor Relations
Anne Marie Fields, 212-838-3777
Senior Vice President
afields@lhai.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170531005832/en/